UK markets close in 7 hours 52 minutes
  • FTSE 100

    6,886.20
    -77.44 (-1.11%)
     
  • FTSE 250

    23,428.45
    -230.49 (-0.97%)
     
  • AIM

    1,268.09
    -7.65 (-0.60%)
     
  • GBP/EUR

    1.1683
    -0.0030 (-0.26%)
     
  • GBP/USD

    1.3682
    -0.0055 (-0.40%)
     
  • BTC-GBP

    32,717.56
    -2,535.74 (-7.19%)
     
  • CMC Crypto 200

    1,116.55
    -108.98 (-8.89%)
     
  • S&P 500

    4,432.99
    -40.76 (-0.91%)
     
  • DOW

    34,584.88
    -166.42 (-0.48%)
     
  • CRUDE OIL

    70.92
    -1.05 (-1.46%)
     
  • GOLD FUTURES

    1,751.70
    +0.30 (+0.02%)
     
  • NIKKEI 225

    30,500.05
    +176.75 (+0.58%)
     
  • HANG SENG

    24,074.50
    -846.26 (-3.40%)
     
  • DAX

    15,194.33
    -295.84 (-1.91%)
     
  • CAC 40

    6,453.73
    -116.46 (-1.77%)
     

ImmunoGen Announces Conference Call to Discuss Its Second Quarter 2021 Operating Results

  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

WALTHAM, Mass., July 15, 2021--(BUSINESS WIRE)--ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, July 30, 2021 to discuss its second quarter operating results. Management will also provide a brief update on the business.

Conference Call Information

To access the live call by phone, dial (877) 621-5803; the conference ID is 1789134. The call may also be accessed through the Investors and Media section of the Company’s website, www.immunogen.com. Following the call, a replay will be available at the same location.

ABOUT IMMUNOGEN

ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to TARGET A BETTER NOW™.

Learn more about who we are, what we do, and how we do it at www.immunogen.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210715005001/en/

Contacts

INVESTOR RELATIONS AND MEDIA
ImmunoGen
Courtney O’Konek
781-895-0600
courtney.okonek@immunogen.com

OR

FTI Consulting
Robert Stanislaro
212-850-5657
robert.stanislaro@fticonsulting.com

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting